glp-1 news 2025 november 25 The Access Gap: Mapping Who Can Actually Afford America's Miracle Weight-Loss Drugs Eli Lilly to seek approval

Current FDA Status of Compounded GLP-1s (Shortage List Changes) As of early 2026, the FDA status of compounded GLP-1 medications remains a dynamic and closely watched issue

Multiple systematic reviews comparing PRP to other treatments found that PRP demonstrated significantly greater improvements in pain scores compared to extracorporeal shock wave therapy, corticosteroid injections, and placebo treatments

Long-term, improved insulin sensitivity often translates to a reduced risk of T2D, high blood pressure, heart disease, and other cardiometabolic disease, all of which grow more prevalent in midlife

Direct Delivery: The injections introduce a concentrated dose of glutathione directly into your bloodstream, allowing the antioxidant to work efficiently